Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Palmoplantar-non-Pustular Psoriasis
NCT03998683Phase 3Completed
- Sponsor
- Janssen-Cilag
- Start
- Sep 2019
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of guselkumab in palmoplantar psoriasis, sponsored by Janssen-Cilag. Started Sep 2019; status: completed.
02
Drugs
guselkumab
03
Conditions
palmoplantar psoriasis
Beyond the preview
Go deeper on NCT03998683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03998683.